1. Home
  2. CGEN vs KEQU Comparison

CGEN vs KEQU Comparison

Compare CGEN & KEQU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGEN
  • KEQU
  • Stock Information
  • Founded
  • CGEN 1993
  • KEQU 1906
  • Country
  • CGEN Israel
  • KEQU United States
  • Employees
  • CGEN N/A
  • KEQU N/A
  • Industry
  • CGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • KEQU Medical Specialities
  • Sector
  • CGEN Health Care
  • KEQU Industrials
  • Exchange
  • CGEN Nasdaq
  • KEQU Nasdaq
  • Market Cap
  • CGEN 125.3M
  • KEQU 124.6M
  • IPO Year
  • CGEN 2000
  • KEQU N/A
  • Fundamental
  • Price
  • CGEN $1.65
  • KEQU $40.24
  • Analyst Decision
  • CGEN
  • KEQU
  • Analyst Count
  • CGEN 0
  • KEQU 0
  • Target Price
  • CGEN N/A
  • KEQU N/A
  • AVG Volume (30 Days)
  • CGEN 324.9K
  • KEQU 12.2K
  • Earning Date
  • CGEN 11-10-2025
  • KEQU 12-10-2025
  • Dividend Yield
  • CGEN N/A
  • KEQU N/A
  • EPS Growth
  • CGEN N/A
  • KEQU N/A
  • EPS
  • CGEN N/A
  • KEQU 4.13
  • Revenue
  • CGEN $6,903,000.00
  • KEQU $263,183,000.00
  • Revenue This Year
  • CGEN N/A
  • KEQU N/A
  • Revenue Next Year
  • CGEN $208.08
  • KEQU N/A
  • P/E Ratio
  • CGEN N/A
  • KEQU $9.70
  • Revenue Growth
  • CGEN N/A
  • KEQU 30.09
  • 52 Week Low
  • CGEN $1.13
  • KEQU $30.33
  • 52 Week High
  • CGEN $2.66
  • KEQU $71.33
  • Technical
  • Relative Strength Index (RSI)
  • CGEN 46.42
  • KEQU 35.88
  • Support Level
  • CGEN $1.54
  • KEQU $39.46
  • Resistance Level
  • CGEN $1.79
  • KEQU $42.91
  • Average True Range (ATR)
  • CGEN 0.11
  • KEQU 1.26
  • MACD
  • CGEN -0.01
  • KEQU 0.01
  • Stochastic Oscillator
  • CGEN 34.62
  • KEQU 21.52

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

About KEQU Kewaunee Scientific Corporation

Kewaunee Scientific Corp is a designer and manufacturer of technical furniture products for industries investing in spaces where discovery occurs, typically in laboratories. It serves in end-use markets that are all commercial, Life sciences, pharma, education, government and military research, etc. The company operates through two segments: The domestic segment designs manufactures and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, laminate casework, flexible systems, and Others; The International segment provides facility design, engineering, construction, and project management from the planning stage through the testing and commissioning of laboratories. It generates the majority of its revenue from the Domestic business segment.

Share on Social Networks: